The American Diabetes Association standards of care - 2023 guidelines provide recommendations for healthcare providers regarding cardiovascular disease (CVD) and risk management in people with diabetes. The authors highlight that atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are leading causes of morbidity and mortality for people with diabetes, noting that simultaneously addressing cardiovascular (CV) risk factors can con...
American Diabetes Association recommendations for cardiovascular disease in diabetes
The American Diabetes Association standards of care - 2023 guidelines provide recommendations for healthcare providers regarding cardiovascular disease (CVD) and risk management in people with diabetes. The authors highlight that atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are leading causes of morbidity and mortality for people with diabetes, noting that simultaneously addressing cardiovascular (CV) risk factors can confer large benefits in patient outcomes.
For prevention and management of ASCVD and HF in people with type 1 or type 2 diabetes, the guidelines recommend that CV risk factors including hypertension and dyslipidaemia are assessed at least annually. Blood pressure should be measured at each routine clinical visit and all people with hypertension and diabetes should monitor their blood pressure at home as part of ongoing assessment of anti-hypertensive treatment. The authors also highlight the benefits of at-home blood pressure monitoring to confirm or negate a diagnosis, to identify white coat or masked hypertension and in improving medication adherence. In these updated guidelines, blood pressure treatment goals are revised to a target of <130/80 mmHg in people with diabetes. A lipid profile (total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol and triglycerides) should be obtained upon diagnosis of diabetes and at least every five years for people aged <40 years and always before initiating statins.
In summarising the clinical approach, the authors highlight the importance of CV risk monitoring and cardioprotective treatment for CV risk reduction in people with diabetes with, or at high risk of ASCVD or HF, even if additional glucose lowering is required.
The full publication can be accessed here.
ElSayed, et al. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of care in diabetes - 2023. Diabetes Care. 2023;46(Suppl. 1):S158-S190
© 2023 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. COL-20364 06/2023
© 2023 Abt. Alle Rechte vorbehalten. Alle genannten Marken sind Marken der Abbott-Unternehmensgruppe oder ihrer jeweiligen Eigentümer.
The Kidney Disease: Improving Global Outcomes (KIDGO) 2022 clinical practice guidelines are based on a systematic review of evidence and aim to assist health care professionals with their decision making for people with diabetes and chronic kidney disease (CKD). The authors highlight that by 2045, 784 million people are estimated to have diabetes globally, of whom ≥40% will develop CKD, potentially leading to kidney failure requiring dialysis or ...
KIDGO clinical practice guidelines: diabetes management in chronic kidney diseaseenMehr Erfahren
The objective of this longitudinal cohort study was to determine the prevalence of chronic kidney disease (CKD) and associated risk factors in a rural South African population. The authors note that infectious and non-communicable disease are a substantial risk for CKD in Africa, but that heterogeneity in assessment and diagnostic criteria hamper the interpretation of prevalence.
Chronic kidney disease prevalence and risks in rural South AfricaenMehr Erfahren
The objective of this cross-sectional, primary care analysis in adults with chronic kidney disease (CKD) was to investigate the association between albuminuria testing and the likelihood of receiving nephrology care. The authors note that measurement of both estimated glomerular filtration rate (eGFR) and albuminuria (urine albumin-creatinine ratio) are necessary for effective risk stratification for CKD, but that albuminuria testing remains wide...
Albuminuria testing in adults with chronic kidney diseaseenMehr Erfahren